B. Riley Securities Downgrades Mirati Therapeutics to Neutral, Lowers Price Target to $60
Portfolio Pulse from Benzinga Newsdesk
B. Riley Securities analyst Kalpit Patel has downgraded Mirati Therapeutics from Buy to Neutral and lowered the price target from $65 to $60.
October 09, 2023 | 1:13 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Mirati Therapeutics has been downgraded from Buy to Neutral by B. Riley Securities, with a lowered price target from $65 to $60.
The downgrade from Buy to Neutral by B. Riley Securities and the lowering of the price target from $65 to $60 indicates a less optimistic outlook for Mirati Therapeutics. This could potentially lead to a decrease in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100